Ronald D.  Sugar net worth and biography

Ronald Sugar Biography and Net Worth

Director of Amgen
Chevron Committees: Board Nominating and Governance; Management Compensation

Current Public Company Directorships: Amgen Inc.; Apple Inc.; Uber Technologies, Inc.

Dr. Sugar is a senior advisor to various businesses and organizations, including Ares Management LLC, a private investment firm; Bain & Company, a global consulting firm; Temasek Americas Advisory Panel, a private investment company based in Singapore; and the G100 and World 50 peer-to-peer exchanges for current and former senior executives and directors from some of the world’s largest companies. He is also an advisor to Northrop Grumman Corporation (“Northrop Grumman”), a global aerospace and defense company, and was previously Northrop Grumman’s Chairman and Chief Executive Officer, from 2003 until his retirement in 2010, and President and Chief Operating Officer, from 2001 until 2003. He joined Northrop Grumman in 2001, having previously served as President and Chief Operating Officer of Litton Industries, Inc., a developer of military products, and earlier as an executive of TRW Inc., a developer of missile systems and spacecraft.

Prior Public Company Directorships (within last five years): Air Lease Corporation

Other Directorships and Memberships: Los Angeles Philharmonic Association; National Academy of Engineering; Nexli Building Solutions, Inc.; UCLA Anderson School of Management Board of Visitors; University of Southern California

Skills and Qualifications

Business Leadership / Operations: Served seven years as CEO of Northrop Grumman. Held senior management and executive positions, including service as COO, at Northrop Grumman, Litton Industries, Inc., and TRW Inc.

Environmental Affairs: As Chairman, CEO, and President of Northrop Grumman, oversaw environmental assessments and remediations at shipyards and aircraft and electronics factories.

Finance: Former CFO of Fortune 500 company. More than three decades of financial responsibility and experience at Northrop Grumman, Litton Industries, Inc., and TRW Inc. Current Audit Committee Chair at Apple Inc. and former Audit Committee Chair at Chevron.

Global Business / International Affairs: Former CEO of Fortune 500 company with extensive international operations. Current and former director of companies with international operations.

Government / Regulatory / Public Policy: At Northrop Grumman, a key government contractor, oversaw development of weapons and other technologies. Appointed by the President of the United States to the National Security Telecommunications Advisory Committee. Former director of the World Affairs Council of Los Angeles.

Science / Technology / Engineering: B.S., M.S., and Ph.D. in engineering from the University of California at Los Angeles. Served in a variety of senior management and executive positions at Northrop Grumman, Litton Industries, Inc., and TRW Inc., requiring expertise in engineering and technology. Director at Amgen Inc., a biotechnology company; Apple Inc., a designer, manufacturer, and marketer of, among other things, personal computers and mobile communication and media devices; Uber Technologies, Inc., a technology company; and former director at BeyondTrust, a global cybersecurity company. Member of National Academy of Engineering.

What is Ronald D. Sugar's net worth?

The estimated net worth of Ronald D. Sugar is at least $4.55 million as of May 12th, 2021. Mr. Sugar owns 16,927 shares of Amgen stock worth more than $4,552,178 as of April 19th. This net worth approximation does not reflect any other investments that Mr. Sugar may own. Learn More about Ronald D. Sugar's net worth.

How do I contact Ronald D. Sugar?

The corporate mailing address for Mr. Sugar and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at [email protected]. Learn More on Ronald D. Sugar's contact information.

Has Ronald D. Sugar been buying or selling shares of Amgen?

Ronald D. Sugar has not been actively trading shares of Amgen during the past quarter. Most recently, Ronald D. Sugar sold 1,000 shares of the business's stock in a transaction on Wednesday, May 12th. The shares were sold at an average price of $250.59, for a transaction totalling $250,590.00. Following the completion of the sale, the director now directly owns 16,927 shares of the company's stock, valued at $4,241,736.93. Learn More on Ronald D. Sugar's trading history.

Who are Amgen's active insiders?

Amgen's insider roster includes Robert Bradway (Chairman & CEO), Robert Eckert (Director), Murdo Gordon (EVP), Jonathan Graham (EVP), Peter Griffith (Exec. VP & CFO ), Nancy Grygiel (SVP), Nancy Grygiel (SVP), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.

Are insiders buying or selling shares of Amgen?

During the last year, Amgen insiders bought shares 1 times. They purchased a total of 1,764,705 shares worth more than $29,999,985.00. During the last year, insiders at the medical research company sold shares 3 times. They sold a total of 21,654 shares worth more than $5,808,676.82. The most recent insider tranaction occured on December, 4th when SVP Nancy A Grygiel sold 2,096 shares worth more than $572,270.88. Insiders at Amgen own 0.5% of the company. Learn More about insider trades at Amgen.

Information on this page was last updated on 12/4/2023.

Ronald D. Sugar Insider Trading History at Amgen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2021Sell1,000$250.59$250,590.0016,927View SEC Filing Icon  
4/14/2021Sell1,000$249.98$249,980.0016,927View SEC Filing Icon  
3/10/2021Sell1,000$231.53$231,530.0016,805View SEC Filing Icon  
2/10/2021Sell1,000$238.40$238,400.0016,805View SEC Filing Icon  
1/13/2021Sell1,000$235.99$235,990.0016,805View SEC Filing Icon  
8/19/2020Sell1,000$241.02$241,020.00
7/22/2020Sell1,000$259.79$259,790.0016,589View SEC Filing Icon  
6/17/2020Sell1,000$228.54$228,540.0016,576View SEC Filing Icon  
5/20/2020Sell1,000$229.27$229,270.0016,482View SEC Filing Icon  
4/22/2020Sell1,000$233.35$233,350.0015,636View SEC Filing Icon  
10/2/2019Sell2,000$193.58$387,160.0016,436View SEC Filing Icon  
9/4/2019Sell2,000$206.70$413,400.0016,336View SEC Filing Icon  
7/3/2019Sell2,000$187.58$375,160.0016,336View SEC Filing Icon  
6/5/2019Sell2,000$175.68$351,360.0016,219View SEC Filing Icon  
5/1/2019Sell2,000$175.73$351,460.0015,092View SEC Filing Icon  
4/3/2019Sell2,000$193.18$386,360.0015,092View SEC Filing Icon  
3/6/2019Sell2,000$188.88$377,760.0014,988View SEC Filing Icon  
2/7/2019Sell2,000$190.00$380,000.0014,988View SEC Filing Icon  
See Full Table

Ronald D. Sugar Buying and Selling Activity at Amgen

This chart shows Ronald D Sugar's buying and selling at Amgen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amgen Company Overview

Amgen logo
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Read More

Today's Range

Now: $268.93
Low: $260.68
High: $269.38

50 Day Range

MA: $277.34
Low: $262.75
High: $294.43

2 Week Range

Now: $268.93
Low: $211.71
High: $329.72

Volume

3,380,202 shs

Average Volume

2,858,917 shs

Market Capitalization

$144.12 billion

P/E Ratio

21.53

Dividend Yield

3.39%

Beta

0.58